FDMT. – 4D Molecular Therapeutics Inc
Float Short %
10.08
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
0.09
EPS Last/This Y
-0.71
EPS This/Next Y
-0.11
Price
6.81
Target Price
28.78
Analyst Recom
1.82
Performance Q
51.33
Relative Volume
0.46
Beta
2.86
Ticker: FDMT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | FDMT | 7.26 | 0.13 | 0.01 | 8036 |
| 2025-08-18 | FDMT | 7.28 | 0.05 | 0.01 | 4062 |
| 2025-08-19 | FDMT | 6.57 | 0.06 | 0.02 | 4009 |
| 2025-08-20 | FDMT | 6.85 | 0.05 | 0.00 | 4868 |
| 2025-08-21 | FDMT | 6.85 | 0.05 | 0.00 | 4790 |
| 2025-08-22 | FDMT | 7.1 | 0.05 | 0.01 | 4808 |
| 2025-08-25 | FDMT | 6.75 | 0.05 | 0.16 | 4821 |
| 2025-08-26 | FDMT | 6.55 | 0.05 | 0.31 | 4852 |
| 2025-08-27 | FDMT | 6.47 | 0.05 | 0.19 | 4817 |
| 2025-08-28 | FDMT | 6.17 | 0.05 | 0.06 | 4856 |
| 2025-08-29 | FDMT | 6.16 | 0.05 | 0.16 | 4901 |
| 2025-09-02 | FDMT | 6.14 | 0.05 | 0.16 | 4950 |
| 2025-09-03 | FDMT | 6.47 | 0.05 | 0.04 | 5006 |
| 2025-09-04 | FDMT | 6.61 | 0.05 | 1.07 | 5023 |
| 2025-09-05 | FDMT | 7.26 | 0.07 | 0.00 | 5094 |
| 2025-09-08 | FDMT | 6.97 | 0.06 | 0.20 | 5521 |
| 2025-09-09 | FDMT | 6.98 | 0.06 | 0.13 | 5608 |
| 2025-09-10 | FDMT | 6.95 | 0.06 | 0.03 | 5640 |
| 2025-09-11 | FDMT | 7.07 | 0.06 | 0.48 | 5760 |
| 2025-09-12 | FDMT | 6.8 | 0.07 | 0.20 | 5750 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | FDMT | 7.27 | -10.0 | - | -3.70 |
| 2025-08-18 | FDMT | 7.26 | -10.0 | - | -3.70 |
| 2025-08-19 | FDMT | 6.57 | -10.0 | - | -3.70 |
| 2025-08-20 | FDMT | 6.86 | -10.0 | - | -3.70 |
| 2025-08-21 | FDMT | 6.85 | -10.0 | - | -3.70 |
| 2025-08-22 | FDMT | 7.09 | -24.6 | - | -3.69 |
| 2025-08-25 | FDMT | 6.74 | -24.6 | - | -3.69 |
| 2025-08-26 | FDMT | 6.53 | -24.6 | - | -3.69 |
| 2025-08-28 | FDMT | 6.18 | -24.6 | - | -3.69 |
| 2025-08-29 | FDMT | 6.16 | -24.6 | - | -3.69 |
| 2025-09-02 | FDMT | 6.13 | -24.6 | - | -3.69 |
| 2025-09-03 | FDMT | 6.47 | -24.6 | - | -3.69 |
| 2025-09-04 | FDMT | 6.61 | -24.6 | - | -3.69 |
| 2025-09-05 | FDMT | 7.27 | -24.6 | - | -3.69 |
| 2025-09-08 | FDMT | 6.97 | -24.6 | - | -3.69 |
| 2025-09-09 | FDMT | 6.97 | -24.6 | - | -3.69 |
| 2025-09-10 | FDMT | 6.95 | -24.6 | - | -3.69 |
| 2025-09-11 | FDMT | 7.07 | -24.6 | - | -3.69 |
| 2025-09-12 | FDMT | 6.81 | -24.6 | - | -3.69 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | FDMT | 0.00 | -7.30 | 8.84 |
| 2025-08-18 | FDMT | 0.00 | -8.81 | 8.69 |
| 2025-08-19 | FDMT | 0.00 | -8.81 | 8.69 |
| 2025-08-20 | FDMT | 0.00 | -8.81 | 8.69 |
| 2025-08-21 | FDMT | 0.00 | -8.81 | 8.69 |
| 2025-08-22 | FDMT | 0.00 | -8.81 | 8.69 |
| 2025-08-25 | FDMT | 0.00 | -9.09 | 8.69 |
| 2025-08-26 | FDMT | 0.00 | -9.09 | 8.69 |
| 2025-08-27 | FDMT | 0.00 | -9.09 | 9.72 |
| 2025-08-28 | FDMT | 0.00 | -9.09 | 9.72 |
| 2025-08-29 | FDMT | 0.00 | -9.09 | 9.72 |
| 2025-09-02 | FDMT | 0.00 | -9.05 | 9.72 |
| 2025-09-03 | FDMT | 0.00 | -9.05 | 9.72 |
| 2025-09-04 | FDMT | 0.00 | -9.05 | 9.72 |
| 2025-09-05 | FDMT | 0.00 | -9.05 | 9.72 |
| 2025-09-08 | FDMT | 0.00 | -9.04 | 9.72 |
| 2025-09-09 | FDMT | 0.00 | -9.04 | 9.72 |
| 2025-09-10 | FDMT | 0.00 | -9.04 | 9.72 |
| 2025-09-11 | FDMT | 0.00 | -9.04 | 10.08 |
| 2025-09-12 | FDMT | 0.00 | -9.04 | 10.08 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.98
Avg. EPS Est. Current Quarter
-0.98
Avg. EPS Est. Next Quarter
-0.89
Insider Transactions
Institutional Transactions
-9.04
Beta
2.86
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
18
Growth Score
28
Sentiment Score
48
Actual DrawDown %
87.6
Max Drawdown 5-Year %
Target Price
28.78
P/E
Forward P/E
PEG
P/S
10601.57
P/B
0.76
P/Free Cash Flow
EPS
-3.71
Average EPS Est. Cur. Y
-3.69
EPS Next Y. (Est.)
-3.81
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-594375.76
Relative Volume
0.46
Return on Equity vs Sector %
-71.5
Return on Equity vs Industry %
-58.3
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.14
EBIT Estimation
4D Molecular Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading